Live Breaking News & Updates on Cell Surface

Stay updated with breaking news from Cell surface. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the

Nineteen abstracts accepted, including multiple presentations on the safety and efficacy of investigational epcoritamab (DuoBody®-CD3xCD20) in a variety of treatment settings and hematologic malignanciesFour oral presentations highlighting data evaluating epcoritamab for the treatment of relapsed/refractory (R/R) la. ....

Al Qahirah , United States , New Orleans , New Jersey , David Freundel , Epcoritamab Duobody , Epcoritamab Monotherapy , Judith Klimovsky , Exposition Of The American Society Hematology , Product Communications , Macrophage Propertiesj Immunol , Ernestn Morial Convention Center , American Society Of Hematology , Exchange Commission , Health Care Resource Utilization , Development Of Novel Anti , Company Announcement , Annual Meeting , American Society , Convention Center , Executive Vice President , Chief Development Officer , Yearly Results , Refractory Diffuse Largeb Cell Lymphoma Eligible , Autologous Stem Cell Transplant , Updated Phase ,

Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH)

03.11.2022 - Media Release Copenhagen, Denmark, November 3, 2022 Nineteen abstracts accepted, including multiple presentations on the safety and efficacy of investigational epcoritamab (DuoBody-CD3xCD20) in a variety of treatment settings and hematologic . ....

Al Qahirah , United States , New Jersey , David Freundel , Kalvebod Brygge , Epcoritamab Monotherapy , Judith Klimovsky , Andrew Carlsen , Product Communications , Macrophage Propertiesj Immunol , Exchange Commission , American Society Of Hematology , Health Care Resource Utilization , Development Of Novel Anti , Company Announcement , Executive Vice President , Chief Development Officer , American Society , Yearly Results , Refractory Diffuse Largeb Cell Lymphoma Eligible , Autologous Stem Cell Transplant , Updated Phase , Refractory Follicular Lymphoma , First Line Treatment , Follicular Lymphoma , Initial Results ,

Genmab A/S: Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH)

Nineteen abstracts accepted, including multiple presentations on the safety and efficacy of investigational epcoritamab (DuoBody-CD3xCD20) in a variety of treatment settings and hematologic malignancies ....

Al Qahirah , United States , New Orleans , New Jersey , David Freundel , Epcoritamab Monotherapy , Judith Klimovsky , Andrew Carlsen , Rituximab Lenalidomide , Exposition Of The American Society Hematology , Product Communications , Macrophage Propertiesj Immunol , Ernestn Morial Convention Center , American Society Of Hematology , Exchange Commission , Health Care Resource Utilization , Development Of Novel Anti , Company Announcement , Annual Meeting , American Society , Convention Center , Executive Vice President , Chief Development Officer , Yearly Results , Refractory Diffuse Largeb Cell Lymphoma Eligible , Autologous Stem Cell Transplant ,

AbbVie Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Large B-Cell Lymphoma (LBCL)

/PRNewswire/ AbbVie (NYSE: ABBV) today announced that the European Medicines Agency (EMA) has validated a Marketing Authorization Application (MAA) for. ....

Mohamed Zaki , Genmab Duobody , Macrophage Propertiesj Immunol , Drug Administration , Exchange Commission , Development Of Novel Anti , European Medicines Agency , Marketing Authorization Application , Biologics License Application , Diffuse Largeb Cell Lymphoma , Largeb Cell Lymphoma , Allergan Aesthetics , Private Securities Litigation Reform Act , Quarterly Reports , Clinically Utilized , Directed Antibodies , Macrophage Properties , Novel Anti Cd , Cell Surface , Cancer Sci ,

Genmab A/S: Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DLBCL)

Genmab has Submitted Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) for epcoritamab European Medicines Agency (EMA) has validated Marketing Authorization Application ....

New Jersey , United States , David Freundel , Andrew Carlsen , Product Communications , Macrophage Propertiesj Immunol , Drug Administration , Exchange Commission , Meeting Of The European Hematology Association , Development Of Novel Anti , European Medicines Agency , Diffuse Large Lymphoma Research Foundation , Submitted Biologics License Application , Medicines Agency , Marketing Authorization Application , Biologics License Application , Presidential Symposium , Annual Meeting , European Hematology Association , Chief Executive Officer , Largeb Cell Lymphoma , Diffuse Largeb Cell Lymphoma , Media Release , Annual Report , Y Shaped Genmab , Rev Oncol ,